ClinicalTrials.gg
CompletedNCT07105371Updated Nov 12, 2026

Patients With ALS and Other Motor Disorders Will be Treated With Umbilical or Placental Mesenchymal Cell Exosome Solution

A Phase 1 interventional study of Exosome Secretome in Motor Disorders, sponsored by The Foundation for Orthopaedics and Regenerative Medicine. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by The Foundation for Orthopaedics and Regenerative Medicine · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Jul 2024, registered Jul 2025).
Updated Nov 12, 2026First sites in Greece and United StatesNo longer in Antigua and Barbuda+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Patients with ALS and other Motor Discorders will be treated with mesenchymal cell exosome solution.

Read the detailed description

Single Arm non-controlled study. Patients are prospectively evaluated then treated. Outcomes are tracked after treatment.

02

Conditions studied

  • Motor Disorders

Keywords

  • exosomes
  • secretome
  • ALS
  • Kennedy disease
  • Congenital Myasthenic Syndrome
  • Lewy body dementia
03

In context

Motor Disorders

73 studies on the registry are indexed under Motor Disorders; 24 are open to participants now.

This study's enrollment of 70 is above the median of 41 across 52 interventional studies indexed under Motor Disorders.

Browse Motor Disorders studies →

Lead sponsor

The Foundation for Orthopaedics and Regenerative Medicine is the lead sponsor of 33 studies on the registry; 19 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients will need a diagnosis established by a neurologist. Patients must be able to provide , or have a guardian who does. They must be able to travel to the site of treatment.

Exclusion criteria

Exclusion Criteria:

  • Patients were excluded from the trial if they were pregnant or had active cancer at the screening consultation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Treatment Group (Exosome Secretome)

    Biological: Exosome Secretome

Interventions

  • BiologicalExosome Secretome

    This is an intranasal treatment of exosomes derived from Umbilical or Placental Derived Mesenchymal Stem Cells.

06

What researchers measure

Primary outcomes

  1. ALSFRS-R Results

    Time frame: from enrollment until 6 months after treatment

07

Study locations

2 sites
  • Prodromos Stem Cell Institute
    Naples, Florida 34102, United States
  • Prodromos Stem Cell Institute
    Athens, Greece
08

References and documents

Publications

  • Prodromos CC, Del Villar R, Jin MY, Abd-Elsayed A, Candido K. Exosome-rich mesenchymal stem cell secretome improves strength in patients with amyotrophic lateral sclerosis, Kennedy disease, congenital myasthenic syndrome and Lewy body dementia. Am J Stem Cells. 2025 Oct 15;14(4):217-229. doi: 10.62347/FTXA8845. eCollection 2025. PubMed 41278139 ↗
09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jul 2024 to primary completion in Oct 2026, 26 months.

Primary completion moved twice since we started tracking on Sep 25, 2026: Mar 2025 → Oct 2026, last on Nov 12, 2026.

Completion moved twice since we started tracking on Sep 25, 2026: Mar 2025 → Oct 2026, last on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2025
First posted
Aug 5, 2025
StartActual
Jul 14, 2024
Primary completionActual
Oct 1, 2026was Mar 2025
CompletionActual
Oct 1, 2026was Mar 2025
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 1 site removed — first sites in Greece and United States; no longer in Antigua and Barbuda
Show 2 added (1 United States, 1 Greece)
  • Prodromos Stem Cell Institute · Naples, United States
  • Prodromos Stem Cell Institute · Athens, Greece
Show 1 removed
  • Medical Surgical Associates Center · St John's, Antigua and Barbuda
Oct 16, 2026
Primary completion
Mar 14, 2025→Oct 1, 2026
moved 2 times, Oct 5, 2026 – Nov 12, 2026
Study completion
Mar 14, 2025→Oct 1, 2026
moved 2 times, Oct 5, 2026 – Nov 12, 2026
Enrollment
18→70
Oct 5, 2026
Interventions
Changed AlloEx exosomes→Exosome Secretome. Arm changed Treatment Group (AlloEx)→Treatment Group (Exosome Secretome)
Oct 5, 2026
Title
Patients With ALS and Other Motor Disorders Will be Treated With Umbilical or Placental Mesenchymal Cell Exosome Solution
Oct 16, 2026
Show all 3 updates
  1. Nov 12, 2026
    Primary completion May 1, 2026→Oct 1, 2026
    Study completion May 14, 2026→Oct 1, 2026
    + 1 other change: verification date
  2. Oct 16, 2026
    2 sites added, 1 site removed — first sites in Greece and United States; no longer in Antigua and Barbuda
    Show 2 added (1 United States, 1 Greece)
    • Prodromos Stem Cell Institute · Naples, United States
    • Prodromos Stem Cell Institute · Athens, Greece
    Show 1 removed
    • Medical Surgical Associates Center · St John's, Antigua and Barbuda
    Title Patients With ALS and Other Motor Disorders Will be Treated With Umbilical or Placental Mesenchymal Cell Exosome Solution
    + 1 other change: arm descriptions
  3. Oct 5, 2026
    Primary completion Mar 14, 2025→May 1, 2026
    Study completion Mar 14, 2025→May 14, 2026
    Enrollment 18→70
    Interventions Changed AlloEx exosomes→Exosome Secretome. Arm changed Treatment Group (AlloEx)→Treatment Group (Exosome Secretome)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07105371
Lead sponsor
The Foundation for Orthopaedics and Regenerative Medicine
Responsible party
Sponsor
First posted
Aug 5, 2025
Start date
Jul 14, 2024
Primary completion
Oct 1, 2026
Completion
Oct 1, 2026
Last update
Nov 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion